The stock of Unicycive Therapeutics Inc (UNCY) has gone down by -13.36% for the week, with a -13.27% drop in the past month and a -31.37% drop in the past quarter. The volatility ratio for the week is 16.93%, and the volatility levels for the past 30 days are 10.69% for UNCY. The simple moving average for the past 20 days is -12.02% for UNCY’s stock, with a -1.46% simple moving average for the past 200 days.
Is It Worth Investing in Unicycive Therapeutics Inc (NASDAQ: UNCY) Right Now?
The stock has a 36-month beta value of 2.17. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for UNCY is 99.26M, and at present, short sellers hold a 1.73% of that float. On April 10, 2025, the average trading volume of UNCY was 1.04M shares.
UNCY) stock’s latest price update
Unicycive Therapeutics Inc (NASDAQ: UNCY) has experienced a decline in its stock price by -0.16 compared to its previous closing price of 0.51. However, the company has seen a fall of -13.36% in its stock price over the last five trading days. globenewswire.com reported 2025-04-01 that LOS ALTOS, Calif., April 01, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, at 2:15 p.m. ET.
Analysts’ Opinion of UNCY
Many brokerage firms have already submitted their reports for UNCY stocks, with Piper Sandler repeating the rating for UNCY by listing it as a “Overweight.” The predicted price for UNCY in the upcoming period, according to Piper Sandler is $9 based on the research report published on April 04, 2024 of the previous year 2024.
UNCY Trading at -11.33% from the 50-Day Moving Average
After a stumble in the market that brought UNCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.13% of loss for the given period.
Volatility was left at 10.69%, however, over the last 30 days, the volatility rate increased by 16.93%, as shares sank -12.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.58% lower at present.
During the last 5 trading sessions, UNCY fell by -13.36%, which changed the moving average for the period of 200-days by -25.12% in comparison to the 20-day moving average, which settled at $0.5810. In addition, Unicycive Therapeutics Inc saw -35.63% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for UNCY
The total capital return value is set at -4.26. Equity return is now at value -2355.27, with -186.02 for asset returns.
Based on Unicycive Therapeutics Inc (UNCY), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -36.97. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -452.35.
Currently, EBITDA for the company is -32.12 million with net debt to EBITDA at 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.28.
Conclusion
To sum up, Unicycive Therapeutics Inc (UNCY) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
